Abstract
Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.
| Original language | English (US) |
|---|---|
| Journal | Clinical Breast Cancer |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Circulating endothelial cells
- Circulating tumor cells
- Erlotinib
- Metastatic
- Nab-paclitaxel bevacizumab
- Triple negative breast cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. / Seattle Cancer Care Alliance Network Investigators.
In: Clinical Breast Cancer, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
AU - Seattle Cancer Care Alliance Network Investigators
AU - Symonds, Lynn
AU - Linden, Hannah
AU - Gadi, Vijayakrishna
AU - Korde, Larissa
AU - Rodler, Eve
AU - Gralow, Julie
AU - Redman, Mary
AU - Baker, Kelsey
AU - Wu, Quan (Vicky)
AU - Jenkins, Isaac
AU - Kurland, Brenda
AU - Garrison, Mitchell
AU - Smith, Julie
AU - Anderson, Jeanne
AU - Van Haelst, Carol
AU - Specht, Jennifer
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.
AB - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.
KW - Circulating endothelial cells
KW - Circulating tumor cells
KW - Erlotinib
KW - Metastatic
KW - Nab-paclitaxel bevacizumab
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85060977590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060977590&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2018.12.008
DO - 10.1016/j.clbc.2018.12.008
M3 - Article
C2 - 30737173
AN - SCOPUS:85060977590
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
ER -